Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

| More on:
Cannabis grows at a commercial farm.

Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

SNDL (NYSE:SNDL) is a Canada-based cannabis stock that is currently trading 94% below all-time highs. SNDL stock has burnt massive investor wealth ever since it was listed as a public company in August 2019. Valued at a market cap of $500 million, SNDL has been among the worst-performing companies in the last 12 months.

The global cannabis market is estimated to expand at a rapid pace in the upcoming decade, especially if the recreational use of marijuana is legalized at the federal level in several regions.

While SNDL is trailing the broader markets by a wide margin, let’s see if it can stage a comeback in 2023.

Is SNDL stock a buy right now?

In the last 12 months, SNDL has reported sales of $494.5 million, an increase of 700% in the last three years. Despite its enviable revenue growth, SNDL reported an operating loss of $52.3 million in the past four quarters. Its gross margin is currently less than 20%, and the company has to increase top line at a robust pace to improve profit margins further.

SNDL is Canada’s largest private-sector cannabis and liquor retailer. It has 169 retail liquor locations, most of which are in Alberta. It also operates 183 cannabis retail outlets under banners such as “Value Buds” and “Spiritleaf.”

While SNDL’s liquor sales were flat year over year in the third quarter (Q3), gross revenue from its cannabis retail segment rose to $66.2 million compared to just $6 million in the year-ago period. Sales growth in Q3 was primarily driven by the acquisition of Nova Cannabis and Value Buds, which brought in $58.9 million in revenue in this period.

Additionally, the company operates an investment portfolio where it deploys strategic capital to other cannabis operators. SNDL has deployed $677.5 million in cannabis-related investments to date. In Q3, its investment portfolio generated interest and fee revenue totaling $4.3 million, compared to $3.3 million in the year-ago period.

What’s next for SNDL stock and investors?

While SNDL is expected to report an EBITDA loss of $49 million in 2022, it’s estimated to end 2023 with an EBITDA (earnings before interest, taxes, depreciation, and amortization) profit of $57 million. Analysts tracking the company also expect its sales to rise to $510 million in 2022 and $707.2 million in 2023.

SNDL stock is valued at less than one times forward sales due to its vulnerable liquidity position. It ended Q3 with $325 million in cash, indicating the company will have to raise capital and support its cash-burn rate.

SNDL will either dilute shareholder wealth or increase balance sheet debt, which will make investors nervous. Further, the Canadian cannabis market is wrestling with a range of structural issues, including a thriving black market, rising inventory levels, goodwill write-downs, and negative profit margins.

SNDL remains focused on creating shareholder value through vertical integration, expansion of retail distribution networks, streamlining operations, and enhancing the offerings of high-quality brands. But to regain investor confidence, SNDL will have to race toward profitability and generate consistent cash flows.

Analysts tracking SNDL stock remain bullish and have a 12-month price target of $4.13, indicating an upside potential of 80%.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »